A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions
- Acronyms CGC
- 26 Jun 2018 Planned End Date changed from 1 May 2020 to 1 Dec 2020.
- 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 May 2020.